Аннотация
На основе международных стандартов молекулярно-генетического типирования легионелл (SBT и EQA протоколов Европейской рабочей группы по легионеллёзу — EWGLI) охарактеризованы штаммы Legionella pneumophila и Legionella species, выделенные в Российской Федерации за последние годы при профилактическом мониторинге и во время эпидемической вспышки, а также представленные в коллекции НИИЭМ им. Н.Ф. Гамалеи РАМН. Установлено, что для 31 нового штамма из 3 регионов РФ характерно 19 аллельных профилей. Показано, что наиболее часто среди отечественных штаммов встречаются профили 1, 4, 3, 1, 1, 1, 6 и 6, 10, 19, 28, 19, 4, 3. Идентифицировано 9 новых аллельных профилей, ранее не зарегистрированных в базе EWGLI. На основе EQA протокола секвенирования mip-гена установлена видовая принадлежность 3 новых штаммов Legionella species: 2 — L. gratiana и 1 — L. gormanii. Ранее идентифицированные виды не тестировались на территории РФ.
-
1.
Kollef M.H. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004; 32:1396-405.
-
2.
Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-92.
-
3.
Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153:1711-25.
-
4.
Rello J., Ollendorf D.A., Oster G., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-21.
-
5.
National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28:429-48.
-
6.
Heyland D.K., Cook D.J., Griffith L., Keenan S.P., BrunBuisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999; 159:1249-56.
-
7.
Warren D.K., Shukla S.J., Olsen M.A., et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31:1312-7.
-
8.
Shorr A.F., Susla G.M., Kollef M.H. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004; 32:137- 43.
-
9.
Hospital-acquired Pneumonia Guideline Committee of the American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388–416.
-
10.
Rello J., Rue M., Jubert P., et al. Survival in patients with nosocomial pneumonia: impact of the severity of illness and the etiologic agent. Crit Care Med 1997; 25:1862-7.
-
11.
Hanes S.D., Demirkan K., Tolley E., et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 35:228-35.
-
12.
Rello J., Sole-Violan J., Sa-Borges M., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33:1983-7.
-
13.
Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
-
14.
Lynch J.P. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119 (2 Suppl): 373S -384S.
-
15.
Combes A., Figliolini C., Trouillet J.L, et al. Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest 2002; 121:1618 –23.
-
16.
Ibrahim E.H., Ward S., Sherman G., Kollef M.H. A comparative analysis of patients with early-onset vs lateonset nosocomial pneumonia in the ICU setting. Chest 2000; 117:1434-42.
-
17.
Flanders S.A., Collard H.R., Saint S. Nosocomial pneumonia: state of the science. Am J Infect Control 2006; 34:84-93.
-
18.
Dore P., Robert R., Grollier G., et al. Incidence of anaerobes in ventilator-associated pneumonia with use of a protected specimen brush. Am J Respir Crit Care Med 1996; 153:1292–8.
-
19.
Marik P.E., Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. Chest 1999; 115:178– 83.
-
20.
Morehead R.S., Pinto S.J. Ventilator-associated pneumonia. Arch Intern Med 2000; 160:1926-36.
-
21.
Fagon J.Y., Chastre J., Domart Y., et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139:877-84.
-
22.
Torres A., Aznar R., Gatell J.M., et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142:523-8.
-
23.
Rello J., Sa-Borges M., Correa H., Leal S.R., Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices.Am J Respir Crit Care Med. 1999; 160:608-13.
-
24.
Страчунский Л.С., Решедько Г.К., Рябкова Е.Л. и др. Рекомендации по оптимизации антимикробной терапии нозокомиальных инфекций, вызванных грамотрицательными бактериями в отделениях реанимации и интенсивной терапии. Клиническая Микробиология и Антимикробная Химиотерапия 2002; 4: 379-90.
-
25.
Reshedko G., Sukhorukova M., Ivanchik N., et al. Antimicrobial resistance of nosocomial gram-negative bacteria in Russian Intensive Care Units (ICUs). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2007, abst. 1539.
-
26.
Kollef M.H., Kollef K.E. Antibiotic utilization and outcomes for patients with clinically suspected ventilatorassociated pneumonia and negative quantitative BAL culture results. Chest 2005; 128:2706 –13.
-
27.
Luna C.M., Videla A., Mattera J., et al. Blood cultures have limited value in predicting severity of illness and as a diagnostic tool in ventilator-associated pneumonia. Chest 1999; 116:1075–84.
-
28.
Muscedere J., Dodek P., Keenan S., Fowler R., Cook D., Heyland D.; for the VAP Guidelines Committee and the Canadian Critical Care Trials Group. Comprehensive evidence-based clinical practice guidelines for ventilatorassociated pneumonia: Diagnosis and treatment. J Crit Care 2008; 23:138-47.
-
29.
Kollef M.H., Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-20.
-
30.
Clec’h C., Timsit J.F., De Lassence A., et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 2004; 30:1327-33.
-
31.
Iregui M., Ward S., Sherman G., Fraser V.J., Kollef M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-8.
-
32.
Dupont H., Mentec H., Sollet J.P., Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-62.
-
33.
Alvarez-Lerma F., ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22:387–94.
-
34.
Luna C.M., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilatorassociated pneumonia. Chest 1997; 111:676-85.
-
35.
Celis R., Torres A., Gatell J.M., Almela M., RodriguezRoisin R., Agusti-Vidal A. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988; 93:318-24.
-
36.
Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Нозокомиальная пневмония у взрослых: практические рекомендации по диагностике, лечению, профилактике. Пособие для врачей. Москва, 2005. 54 с.
-
37.
Pea F., Viale P., Furlanut M. Antimicrobial therapy in critically ill patients. Clin Pharmacokinet 2005; 44:1009- 34.
-
38.
Pinder M., Bellomo R., Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30:134-44.
-
39.
Park D. Antimicrobial treatment of ventilator-associated pneumonia. Resp Care 2005; 507:932-52.
-
40.
Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 261:1-10.
-
41.
Bernabeu-Wittel M., Pichardo C., García-Curiel A., et al. Pharmacokinetic/pharmacodynamic assessment of the in vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 2005; 11:319-25.
-
42.
Siempos I.I., Vardakas K.Z., Manta K.G., Falagas M.E. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007; 29:548-60.
-
43.
Alvarez-Lerma F., Santos F.M., De Castro J., et al. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13:70-81.
-
44.
Sieger B., Berman S.J., Geckler R.W., Farkas S.A. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997; 25:1663-70.
-
45.
Aarts M.A., Hancock J.N., Heyland D., McLeod R.S., Marshall J.C. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008; 36:108-17.
-
46.
Heyland D.K., Dodek P., Muscedere J., Day A., Cook D.; for the Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2007 Dec 12.
-
47.
Rello J., Vidaur L., Sandiumenge A., et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32:2183-90.
-
48.
Ibrahim E.H., Ward S., Sherman G., Schaiff R., Fraser V.J., Kollef M.H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15.
-
49.
Kollef M.H., Niederman M.S., Leeper K.V., et al. Escalation/de-escalation of initial empiric ventilatorassociated pneumonia therapy: interim results from the Assessment of Local Antimicrobial Resistance Measures study. Chest 2004; 126:718S.
-
50.
Yan X.X., Zhang L.J., Cai Z.G., et al. A study of the effectiveness and cost of de-escalation therapy for severe lower airway infection in a respiratory intensive care unit. Zhonghua Jie He He Hu Xi Za Zhi 2007; 30:325-9.
-
51.
Singh N., Rogers P., Atwood C.W., Wagener M.M., Yu V.L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162 (2 Pt 1):505- 11.
-
52.
Chastre J., Wolff M., Fagon J.Y., et al. Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-98.
-
53.
Micek S.T., Ward S., Fraser V.J., Kollef M.H. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-9.
-
54.
Dennesen P.J., Van Der Ven A.J, Kessels A.G., et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-pneumonia. Am J Respir Cri. Care Med 2001; 163:1371-5.
-
55.
Hedrick T.L., McElearney S.T., Smith R.L., Evans H.L., Pruett T.L., Sawyer R.G. Duration of antibiotic therapy for ventilator-associated pneumonia caused by nonfermentative gram-negative bacilli. Surg Infect 2007; 8:589-97.
-
56.
Ioannidou E., Siempos I.I., Falagas M.E. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a metaanalysis. J Antimicrob Chemother. 2007; 60:1216-26.
-
57.
Koulenti D., Rello J. Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opin Pharmacother 2006; 7:1555-69.
-
58.
Garnacho J., Sole-Violan J., Sa-Borges M., Diaz E., Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003; 31:2478-82.
-
59.
Falagas M., Kopterides P., Siempos I. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis. 2006;43:389.
-
60.
Albrecht M., Griffith M., Murray C., et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006; 203:546–50.
-
61.
Sunenshine R., Wright M., Maragakis L. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13:97–103.
-
62.
Garnacho-Montero J., Ortiz-Leyba C., FernándezHinojosa E., et al. Acinetobacter baumannii ventilatorassociated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005 May;31(5):649-55.
-
63.
Suwangpool P., Leelasupasri S., Chuchottaworn C. Treatment of nosocomial pneumonia with cefoperazone/ sulbactam. J Infect Dis Antimicrob Agents 1999; 16: 65- 8.
-
64.
Paterson D.L., Ko W.C., Von Gottberg A., e.a. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004; 39: 31-7.
-
65.
Byl B., Jacobs F., Roucloux I., de Franquen P., Cappello M., Thys J.P. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob Agents Chemother 1999; 43:681-2.
-
66.
Tomaselli F., Maier A., Matzi V., Smolle-Jüttner F.M., Dittrich P. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004; 48:2228-32.
-
67.
Odenholt-Tornqvist I. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J Antimicrob Chemother 1993; 31:881-92.
-
68.
Hanberger H., Svensson E., Nilsson L.E., Nilsson M. Control-related effective regrowth time and post-antibiotic effect of meropenem on gram-negative bacteria studied by bioluminescence and viable counts.J Antimicrob Chemother 1995; 35:585-92.
-
69.
Hanberger H., Svensson E., Nilsson L.E., Nilsson M. Pharmacodynamic effects of meropenem on gram-negative bacteria. Eur J Clin Microbiol Infect Dis 1995; 14:383-90.
-
70.
Hikida M., Yamazaki Y., Yoshida M., Kawashima K., Nishiki K., Mitsuhashi S. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa. J Antibiot 1995; 48:891-2.
-
71.
Conte J.E., Golden J.A., Kelley M.G., Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 2005; 26:449- 56.
-
72.
Colardyn F., Faulkner K.L. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996; 38:523-37.
-
73.
Garau J., Blanquer J., Cobo L., et al. Prospective, randomized, multicentre study of meropenem versus imipenem/ cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997; 16:789- 96.
-
74.
Hartenauer U., Kljucar S., Bender H.-J., Weilemann S., Nusser H., Bodmann K.F. Meropenam versus imipenem/ cilastatin for the treatment of serious bacterial infectious in ICU. Antiinfective Drugs Chemotherapy 1997; 15:65- 70.
-
75.
Santos S.S., Machado F.R., Kiffer C.R., Barone A.A. Treatment of nosocomial pneumonia: an experience with meropenem. Braz J Infect Dis 2001; 5:124-9.
-
76.
Berman S.J., Fogarty C.M., Fabian T., et al. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother 2004; 16:362 –71.
-
77.
Verwaest C., Belgian Multicenter Study Group. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000; 6:294-302.
-
78.
Lorente L., Lorenzo L., Martin M.M., Jimenez A., Mora M.L. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gramnegative bacilli. Ann Pharmacother 2006; 40:219-23.